BioStrand Revolutionizes Sequence Retrieval Via NLP And Database Fusion
ImmunoPrecise Antibodies Ltd.'s BioStrand subsidiary made a significant stride by unveiling a groundbreaking white paper, "New Paradigm for Biological Sequence Retrieval," pioneering HYFT-based methodology. This approach, trumping the widely used BLAST algorithm, tokenizes sequences into unique HYFT patterns, offering enhanced precision and scalability without compromising data accuracy. Dirk Van Hyfte, BioStrand's Co-Founder, believes this method, harnessing increased sequence data, will drive discourse and collaboration in bioinformatics.
In addition, BioStrand launched LENSai, a cutting-edge AI platform that integrates a comprehensive knowledge graph linking 25 billion relationships across biological data, enabling a deeper understanding of genetic, structural, and functional interconnections. Leveraging ontology-driven NLP and AI-driven LLMs, LENSai harmonizes syntactic and semantic data, propelling drug discovery and development.
As part of the IPA Family, ImmunoPrecise Antibodies Ltd. leverages advanced AI and systems biology in bioplatform-based antibody discovery. Their suite of services spans therapeutic biologics discovery, development, and out-licensing, supporting partners in addressing complex targets. Visit www.ipatherapeutics.com for more details.
Comments
Post a Comment